Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 29 Adenocarcinoma of Lung 5 NSCLC 4 Meningeal Carcinomatosis 4 Brain Neoplasms 4 Lung Neoplasms 3 Pleural Effusion, Malignant 1 Non Small Cell Lung Cancer NSCLC 1 Neoplasm, Residual 1 Multiple Primary Lung Cancers 1 EGF-R Positive Non-Small Cell Lung Cancer 1 Carcinoma 1 Adenocarcinoma 1

Interventions

Oxaliplatin 32 Fluorouracil 24 Gemcitabine 23 Leucovorin 19 Docetaxel 19 pembrolizumab 17 Capecitabine 15 Radiotherapy 14 Irinotecan 13 Cisplatin 11 Bevacizumab 11 Nivolumab 8 130-nm albumin-bound paclitaxel 8 Trastuzumab 7 Erlotinib Hydrochloride 7 Cyclophosphamide 7 Albumin-Bound Paclitaxel 7 Radiosurgery 6 Paclitaxel 6 Taxes 5 S 1 (combination) 5 Metformin 5 Carboplatin 5 Blood Specimen Collection 5 Sunitinib 4 Sorafenib 4 Pemetrexed 4 Esophagectomy 4 Chemoradiotherapy 4 Cetuximab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Adenocarcinoma × aflutinib × Clear all

NCT04401059 2023-12-27

SELECT-2

Hangzhou Normal University

Phase 4 Unknown

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡